The Expedited Access to Biosimilars Act aims to streamline and accelerate the approval process for biosimilar medications, which are biologic products that are highly similar to already approved reference products. This legislation is intended to increase competition in the pharmaceutical market, potentially lowering drug costs and improving patient access to these treatments.
Supporters of the Expedited Access to Biosimilars Act have praised it for its potential to enhance patient access to affordable medications and promote competition in the pharmaceutical industry. They argue that by expediting the approval process, the bill could lead to significant cost savings for consumers and the healthcare system as a whole.
Critics of the Expedited Access to Biosimilars Act express concerns that speeding up the approval process may compromise the safety and efficacy of biosimilars. Some worry that the legislation could lead to insufficient testing and oversight, potentially putting patients at risk. Additionally, there are fears that it may not effectively address the complexities of the biologics market.
The Expedited Access to Biosimilars Act, sponsored by Rand Paul, presents potential conflicts of interest due to significant financial contributions from the health professionals sector, which totals $1.28 billion. This sector is directly related to the bill's subject matter, as biosimilars are a category of biological products that can impact healthcare costs and access. The substantial donations from health professionals raise questions about whether the interests of these donors may influence the legislative process in favor of their financial interests. Additionally, the retired sector, contributing $400 million, may also have indirect interests in healthcare policies affecting their benefits and costs.
Given the overlap between the sponsor's donors and the health industry, voters should be aware that the motivations behind this legislation could be influenced by the financial interests of those who have contributed significantly to the sponsor's campaign. The lobbying activity in this area, while varied, includes undisclosed amounts from several entities, suggesting a lack of transparency that could further complicate the integrity of the legislative process. Voters should consider how these financial ties may affect the outcomes of policies that are crucial for public health.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $1,280,000,000 |
| Total from overlapping industries | $1,280,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| STRIPE, INC. | STRIPE, INC. | $530,000 |
| SAILDRONE INC. | SAILDRONE INC. | $410,042 |
| SAILDRONE INC. | SAILDRONE INC. | $377,725 |
| OUTDOOR ADVERTISING ASSOCIATION OF AMERICA INC | OUTDOOR ADVERTISING ASSOCIATION OF AMERICA, INC. | $158,589 |
| INTERNATIONAL LONGSHOREMEN'S ASSOCIATION | INTERNATIONAL LONGSHOREMEN'S ASSOCIATION | $150,000 |
| ENVIRONMENTAL DEFENSE FUND | BOUNDARY STONE PARTNERS | $30,000 |
| SEEING MACHINES | GRIFFIN STRATEGIES, LLC | $30,000 |
| SAFE KIDS WORLDWIDE | GRIFFIN STRATEGIES, LLC | $30,000 |
| CREATIVE ASSOCIATES INTERNATIONAL, INC. | DEFENDING OUR COUNTRY, LLC | $30,000 |
| IOOS ASSOCIATION | ESP ADVISORS, LLC | $20,000 |
| ATA ACTION | RS GROUP CONSULTING LLC | $6,000 |
| END SEPSIS | CURRENTSTRATEGIC LLC | undisclosed |
| TECHNEST SOLUTIONS S.L.A. DBA FORTRIS ON BEHALF OF NEXUSONE CONSULTING | CURRENTSTRATEGIC LLC | undisclosed |
| SBCC EQUIPMENT | DEFENDING OUR COUNTRY, LLC | undisclosed |
| BAXTER HEALTHCARE CORPORATION | SUMMIT HEALTH CARE CONSULTING | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Rand Paul, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
